trial

Genetic Research in Schizophrenia Using DNA Markers and Clinical Phenotypes

NCTId NCT00108303
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase — · Completed
Enrollment 538 (actual)
Sponsored by VA Office of Research and Development
Primary completion 2008-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
538 (actual)
Study type
Observational
Allocation
—
Model
—
Masking
—
Start
2004-01
Primary completion
2008-12
Eligibility
ALL · 1 Year · 79 Years

Interventions & indications

Drugs
Diagnostic

Sponsors

VA Office of Research and DevelopmentLead Sponsor

Investigators

1
Robert Freedman, MDPrincipal Investigator

Sites

1 total
Denver, United States

Facts & assertions

4 sourced
Enrollment
538
Phase
NA
Primary Completion Date
2008-12
Status
COMPLETED
relationships
The graph out of here
drug
Diagnostic
drug
lead_sponsor
VA Office of Research and Development
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Robert Freedman, MD
person